Drug intelligence / Profile preview

GB262

Development stage: Preclinical
Lead developer: Genor Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GB262 is a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), an immune checkpoint molecule that negatively regulates T-cell activation. By binding to CTLA-4, GB262 blocks its interaction with the ligands CD80 and CD86 on antigen-presenting cells, thereby preventing the inhibitory signal and enhancing the anti-tumor activity of T cells. Developed by Antibody Therapeutics (in association with Genor Biopharma), the drug is currently in the IND-enabling phase of development, primarily focused on the treatment of advanced solid tumors.

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on GB262.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB262.

Explore the full profile